Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 11/20 | 0.58 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.58 |
| ▸ | KDM4A | O75164 | 1/20 | 0.53 |
| ▸ | KDM4B | O94953 | 1/20 | 0.53 |
| ▸ | KDM5C | P41229 | 1/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.53 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.53 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.51 |
| ▸ | PIM1 | P11309 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157952 | 0.87 | PARP1 (0.56) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| Quinazolinone SCHEMBL88525 | 0.74 | PARP1 (1.00) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL19432 | 0.74 | — | — | |
| Quinazolinone SCHEMBL8201420 | 0.72 | PARP1 (0.96) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| Quinazolinone SCHEMBL30408864 | 0.72 | PARP1 (0.96) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| Quinazolinone SCHEMBL29603643 | 0.72 | PARP1 (0.96) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL10628361 | 0.72 | ALDH1A1 (0.32) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL74789 | 0.69 | — | — | |
| SCHEMBL17796245 | 0.69 | KDM4A (0.53) | PARP1PDPK1CA12ALOX15SMN1; SMN2 | |
| SCHEMBL1886926 | 0.69 | KDM4C (1.00) | PARP1PDPK1CA12ALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 424 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113149885-A | EBNA1 inhibitors and methods of using the same | 威斯塔解剖学和生物学研究所 | 2021-07-23 | — | — | CN | claimed |
| US-20210032242-A1 | AROMATIC HETEROCYCLIC SUBSTITUTED OLEFIN COMPOUND, PREPARATION METHOD FOR SAME, PHARMACEUTICAL COMPOSITION OF SAME, AND APPLICATIONS THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2021-02-04 | — | — | US | claimed |
| US-20180305312-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-10-25 | — | — | US | claimed |
| EP-3294705-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | The Wistar Institute Of Anatomy And Biology (US) | 2018-03-21 | — | — | EP | claimed |
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-15 | — | — | US | claimed |
| EP-1773786-B1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-04-26 | — | — | EP | claimed |
| WO-2016183534-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2016-11-17 | — | — | WO | claimed |
| WO-2016128905-A1 | THIENOPYRROLE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2016-08-18 | — | — | WO | claimed |
| US-20140206706-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-07-24 | — | — | US | claimed |
| US-8716492-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-06 | — | — | US | claimed |
| JP-4791460-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | claimed |
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL -MEYERS SQUIBB COMPANY | 2009-07-16 | — | — | US | claimed |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-05 | — | — | US | claimed |
| EP-1966141-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-09-10 | — | — | EP | claimed |
| WO-2007070818-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2007070816-A2 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | claimed |
| EP-1773786-A2 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2005123050-A2 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-29 | — | — | WO | claimed |
| US-20050282805-A1 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | PARP1 2786/4885PDPK1 2713/4885CA12 2345/4885 |
| US-20180305312-A1 | EBNA1 INHIBITORS AND METHODS USING SAME | MLLT1, EBNA1BP2, MALT1 | PARP1 307/4885PDPK1 3830/4885CA12 3021/4885 |
| US-20210032242-A1 | AROMATIC HETEROCYCLIC SUBSTITUTED OLEFIN COMPOUND, PREPARATION METHOD FOR SAME, PHARMACEUTICAL COMPOSITION OF SAME, AND APPLICATIONS THEREOF | ALK, ALKBH5, ALKBH3 | PARP1 4050/4885PDPK1 1461/4885CA12 4712/4885 |
| US-20140206706-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | PARP1 2786/4885PDPK1 2713/4885CA12 2345/4885 |
| US-20090253766-A1 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | TFPI, F12, F11 | PARP1 3048/4885PDPK1 944/4885CA12 2382/4885 |
| US-20090181983-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | TFPI, F11, F12 | PARP1 2736/4885PDPK1 1668/4885CA12 1593/4885 |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | PARP1 2786/4885PDPK1 2713/4885CA12 2345/4885 |
| US-20050282805-A1 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | F11, TFPI, F12 | PARP1 1847/4885PDPK1 3591/4885CA12 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.